US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inspire Corporate Bond ETF

23.97

+0.05000.21%

Volume:26.68K

Turnover:640.08K

Market Cap:385.92M

PE:- -

High:24.03

Open:24.00

Low:23.92

Close:23.92

Loading ...

Overview Company News Filings

Spyre Therapeutics Announces Grants of Inducement Awards

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Here's How to Play AbbVie Stock as it Enters the Obesity Space

SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

Press Release: Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Press Release: IonQ Announces Fourth Quarter and Full Year 2024 Financial Results

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

Howmet Aerospace Lands On Best Stocks List: Check Out Stock Spotlight, IBD 50, Others

S&P 500 Insurance Broker, IBD Stock Of The Day, Gains On Buy Point After 43% Surge

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Stock Market Shows Positive Reversal, But S&P 500, Nasdaq Trail These Other Indexes; IBD 50 Index Falls

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IBD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.97,"timestamp":1751305269745,"preClose":23.92,"halted":0,"volume":26677,"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"Trading","change":0.05,"latestTime":"06-30 13:50:35 EDT","open":23.9987,"high":24.03,"low":23.9199,"amount":640078.521019,"amplitude":0.004603,"askPrice":23.97,"askSize":300,"bidPrice":23.93,"bidSize":614,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751313600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.92,"sharesOutstanding":16100000,"nav":23.88,"aum":384494668.95,"dividendRate":0.042136,"bidAskSpread":0.001911,"postHourTrading":{"tag":"盘后","latestPrice":23.92,"preClose":23.92,"latestTime":"16:04 EDT","volume":3,"amount":71.76,"timestamp":1751054643139},"volumeRatio":0.844388},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.844388,"shares":16100000,"dividePrice":1.01,"high":24.03,"amplitude":0.004603,"preClose":23.92,"low":23.9199,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":23.97,"committee":0.343545,"eps":0,"divideRate":0.042136,"volume":26677,"delay":0,"ttmEps":0,"open":23.9987,"prevYearClose":23.44,"prevWeekClose":23.92,"prevMonthClose":23.74,"prevQuarterClose":23.75,"fiveDayClose":23.93,"twentyDayClose":23.74,"sixtyDayClose":23.79},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517466136","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2517466136","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517466136?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:40","pubTimestamp":1741383600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 132,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on March 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SYRE","IBD","LENZ","BK4139"],"gpt_icon":0},{"id":"2517803824","title":"BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden","url":"https://stock-news.laohu8.com/highlight/detail?id=2517803824","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517803824?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"Over half of patients had no draining tunnels  at two years: In 425 hidradenitis suppurativa  patients with ≥1 DTs at baseline, 55.7%  had no DTs at two years of treatment.≠ DTs are painful, pus-discharging tunnels under the skin resulting from long-term inflammation, frequently leading to scarring. Clinically meaningful relief from skin pain: At two years of BIMZELX treatment, 63.6%  of patients reported no or mild skin pain, compared to 10.0%  at baseline≠。Sustained disease control across patient populations: Improvements in HiSCR50* and HiSCR75* sustained up to two years, regardless of age, sex, disease duration or severity, demonstrating efficacy regardless of patient demographics≠。ATLANTA, March 7, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX  in moderate-to-severe hidradenitis suppurativa . BIMZELX, the first and only medicine approved to selectively inhibit both interleukin 17A  and interleukin ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-two-data-130000049.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-two-data-130000049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023250843.SGD","LU2360108059.USD","PSO","OC","LU2092937221.SGD","BK4204","BK4007","IE00B2PGVK34.USD","LU1917777945.USD","UCBJF","LU0868494617.USD","LU2106854487.HKD","LU1974910355.USD","AS","BK4111","LU2298321311.HKD","BK4202","IE00B3CCJ633.GBP","LU2041044095.USD","IE00BGHQF417.EUR","BK4086","LU2048586759.USD","LU2023250504.SGD","IBD","UCBJY"],"gpt_icon":0},{"id":"2517480804","title":"BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480804","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480804?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis  treated with BIMZELX  achieved PASI100+ at five years. Durable and broad efficacy across patient subgroups at four years: Consistently high rates of complete or near-complete skin clearance seen at four years regardless of baseline weight or baseline cardiometabolic comorbidities such as hypertension, hyperglycemia, or elevated BMI. High response rates in patients at risk of psoriatic arthritis at three years: Data showed 68.7–71.6% of PSO patients at risk of developing psoriatic arthritis  achieved complete skin clearance, generally consistent with the overall treated group. Similar results were seen in all patients with PSO, including those with PsA at baseline. \"Psoriasis is a chronic condition that increases the risk of developing other serious health issues,\" said Fiona du Monceau, Executive Vice Presiden","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-five-data-130000473.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-five-data-130000473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","UCBJF","BK4111","PSO","UCBJY","BK4204","AS","IBD","BK4007"],"gpt_icon":0},{"id":"2517508511","title":"Organovo Announces the Issuance of Additional Shares  in Conjunction with Warrant Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2517508511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517508511?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:05","pubTimestamp":1741266300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 06, 2025  -- Organovo Holdings, Inc.  , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease  today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/organovo-announces-issuance-additional-shares-130500505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONVO","IBD","BK4139"],"gpt_icon":1},{"id":"2517878943","title":"Here's How to Play AbbVie Stock as it Enters the Obesity Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2517878943","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517878943?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:38","pubTimestamp":1741181880,"startTime":"0","endTime":"0","summary":"Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, along-acting amylin analog for the treatment of obesity, from Danish research company, Gubra.While the obesity field is greatly dominated by GLP-1 products, the amylin hormone is gaining steam as a potential target for treating obesity. It regulates appetiteby slowing down stomach emptying, which makes a person feel full and helps prevent overeating.AbbVie will lead the development of the candidate. For the deal, AbbVie will pay Gubra an upfront payment of $350 millionand be entitled to make milestone payments of up to $1.875 billion to the latter.The obesity market has gained tremendous popularity and is expected to reach $100 billion by 2030, per a Goldman Sachs report. Eli Lilly LLY and Novo Nordisk NVO currently dominate the space with their respective GLP-1 drugs Zepbound and Wegovy. However, several large drugmakers like Merck MRK, Pfizer, Amgen, and AstraZeneca, among","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-play-abbvie-stock-enters-133800732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJLML261.HKD","LU0795875169.SGD","LU0354030438.USD","GB00BDT5M118.USD","LU2023250504.SGD","LU0823416689.USD","LU1548497426.USD","IE00BK4W5M84.HKD","LU0417517546.SGD","LU0198837287.USD","LU1430594728.SGD","SGXZ81514606.USD","LU0553294199.USD","LU0965508806.USD","LU2106854487.HKD","ABBV","LU1093756325.SGD","LU2063271972.USD","SG9999002224.SGD","LU0109391861.USD","SG9999018865.SGD","IBD","LU2491050154.USD","LU0689472784.USD","LU0795875086.SGD","LU0097036916.USD","LU0266013472.USD","LU0006306889.USD","BK4007","SG9999013999.USD","LU0234570918.USD","LU1868837136.USD","BK4559","CD","LU1732800096.USD","LU0320765646.SGD","LU0882574055.USD","LU1699723380.USD","LU1839511570.USD","LU1989772840.SGD","LU1917777945.USD","LU0070302665.USD","IE00B2B36J28.USD","IE00BVYPNW00.USD","LU2491050071.SGD","LU1366192091.USD","MRK","SG9999001176.SGD"],"gpt_icon":1},{"id":"2516676496","title":"SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676496","media":"CNW Group","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676496?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.1. MONTREAL, March 4, 2025 /CNW/ -AbbVie announced today that SKYRIZI  is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis  who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase  inhibitor1, following Health Canada approval of this indication in October 2024. SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.\"We are so grateful for the approval of SKYRIZI for ulcerative colitis and hopeful it will have a positive effect on patient healing,\" said Gail Attara, CEO and co-founder of the Gastrointestinal Society. \"Ulcerative colitis is a debilitating inflammatory bowel disease. Given the uniqueness of each individual, it's essential to bring new treatment options for ulcer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skyrizi-risankizumab-now-available-moderately-130000496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0795875169.SGD","ABBV","LU1267930573.SGD","LU1934455277.USD","LU1496350171.SGD","BK4550","LU1732800096.USD","LU0912757837.SGD","LU2237443978.SGD","BK4534","LU0029864427.USD","LU1037948541.HKD","LU0861579265.USD","LU1732799900.SGD","LU0128525929.USD","BK4566","LU0949170772.SGD","SG9999003800.SGD","IE0009355771.USD","BK4581","LU1430594728.SGD","IE0002141913.USD","LU1291159041.SGD","IE0004445239.USD","LU1983299246.USD","LU2133065610.SGD","LU1244550577.SGD","SG9999015945.SGD","IBD","LU1989772923.USD","LU1267930490.SGD","LU1839511570.USD","LU1037948897.HKD","LU1551013425.SGD","LU1496350502.SGD","LU0661504455.SGD","IE00B4R5TH58.HKD","LU0310800379.SGD","LU1934455194.USD","LU1244550494.USD","LU0170899867.USD","IE00B3PB1722.GBP","LU0965509101.SGD","LU2089283258.USD","LU0965509283.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","SG9999015986.USD","LU0211328371.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2514433053","title":"Press Release: Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514433053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514433053?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress. Topline data readouts from multiple Phase 2 studies expected throughout 2025. -- VTX2735 in patients with recurrent pericarditis in H2. -- VTX3232 in participants with obesity and cardiometabolic risk factors in. -- VTX3232 biomarker study in patients with early Parkinson's disease in Q2. Cash, cash equivalents and marketable securities balance of $252.9M as of. December 31, 2024 expected to fund operations into at least H2 2026. results are expected in the second half of 2025.By treating and preventing disease recurrence, VTX2735 has the potential to offer a safe, effective, and convenient oral therapy for patients suffering from recurrent pericarditis.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","PRGS","IBD","VTYX","LU2065732104.USD"],"gpt_icon":0},{"id":"2514180598","title":"Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180598","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514180598?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"KT-621  Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025. KT-621 Phase 1b trial in atopic dermatitis  patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively. KT-295  Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25. KT-474/SAR444656  Phase 2b trials in hidradenitis suppurativa  and AD ongoing, led by partner Sanofi, with primary completion of both trials expected by mid-2026. New oral degrader program against a high-value immunology target to be announcedin early May 2025 in a company webcast. STAT6 Degrader ProgramKT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. In preclinical studies, KT-621 demonstrated dupilumab-like activity in several in vitro and in vivo models and was safe and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-announces-fourth-quarter-120000004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PN","BK4139","IBD","LENZ","KYMR"],"gpt_icon":0},{"id":"2514896706","title":"Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896706","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896706?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:30","pubTimestamp":1740609000,"startTime":"0","endTime":"0","summary":"Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter. Financial Results and Operational Update for Half-Year Ended December 31, 2024. NEW YORK, Feb. 26, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2024,\"Our FDA approved product Ryoncil will be available in the coming weeks to the children with SR-aGvHD in need of life-saving therapy,\" said Dr. Silviu Itescu, Chief Executive of Mesoblast. \"The treatment has delivered long-term survival outcomes in these very high-risk patients and we are pleased with the benefits and value that this treatment brings to patients and their healthcare providers at specialized transplant centers across the U.S.\". Ryoncil  U.S. Launch for Steroid-Refractory Acute Graft Versus Host Disease. FDA approved Ryoncil as the first and only therapy for pediat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MMAT","MSB.AU","BK4099","ORR","BK4150","BK4183","BK4555","BK4551","CD","BK4022","BK4232","IBD","BK7067","BK7501","03160","WAC","BK4161","BK4546","DDD","BK4575","BK4139","BK4588","MSC","BK4585","BK4170","BK4116","BK4604","MESO","BK7508","TM","BK4141","R","ODD"],"gpt_icon":1},{"id":"2514860594","title":"Press Release: IonQ Announces Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514860594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514860594?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603900,"startTime":"0","endTime":"0","summary":"Exceeds High End of Guidance Range with Full Year Revenue of $43.1. Exceeds High End of Guidance Range with Full Year Bookings of $95.6. Leading Quantum Networking Provider, to Further IonQ's Global Quantum. IonQ , a leader in the quantum computing and networking industries, today announced financial results for the quarter and full year ended December 31, 2024.\"We had IonQ's best year yet in 2024, exceeding the high ends of both our bookings and revenue guidance ranges and making truly significant technical strides,\" said Peter Chapman, IonQ's Executive Chair.\"As we enter 2025, IonQ has a strong pipeline that we believe will enable us to lead in the era of commercial advantage. Last year, our rapidly expanding quantum networking business line closed three major networking contracts. McKinsey expects the quantum networking industry to be worth $10-15 billion per year within the next decade,\" noted Chapman.IonQ recognized revenue of $11.7 million for the quarter, exceeding the. IonQ rec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4170","IONQ","BK4602","BK4591","IBD"],"gpt_icon":1},{"id":"2514837063","title":"Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837063","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837063?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:19","pubTimestamp":1740575940,"startTime":"0","endTime":"0","summary":"Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales of the products in the EUFo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032903/0/en/Biomerica-Achieves-IVDR-Certification-in-the-European-Union-for-Food-Intolerance-Tests-Targeting-Crohn-s-Disease-and-Ulcerative-Colitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IBD","BMRA"],"gpt_icon":0},{"id":"2514099424","title":"Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099424","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099424?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:05","pubTimestamp":1740488700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  25, 2025  (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approac","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3ae64dabd38a125634a5edcda736adba","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3032003/37000/en/Organovo-s-FXR-Program-including-FXR314-to-Be-Acquired-by-Eli-Lilly-and-Company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","LU2357305700.SGD","SG9999013999.USD","LU1267930730.SGD","LU2063271972.USD","LU2106854487.HKD","LU2491050071.SGD","LU0256863902.USD","SGXZ99366536.SGD","IBD","ONVO","SGXZ57979304.SGD","LU1023059063.AUD","LU2491050154.USD","LU1093756325.SGD","LU0417517546.SGD","BK4585","SG9999014898.SGD","SGXZ31699556.SGD","IE00BFTCPJ56.SGD","LU0471298694.HKD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU0114720955.EUR","LU1057294990.SGD","IE00BJLML261.HKD","LU0820561818.USD","LU2361044949.HKD","IE0002141913.USD","LU1868837136.USD","FXR","LU0058720904.USD","SGXZ81514606.USD","BK4599","IE00B2B36J28.USD","BK4588","LU1291159041.SGD","LU0203201768.USD","SG9999015978.USD","LU2360106947.USD","LU2461242641.AUD","SG9999018865.SGD","IE0004445239.USD","LU1712237335.SGD","LU1983299246.USD","LU0106261372.USD","BK4534","LLY","LU2112291526.USD","GB00BDT5M118.USD"],"gpt_icon":1},{"id":"2513721338","title":"Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2513721338","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513721338?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:22","pubTimestamp":1740403320,"startTime":"0","endTime":"0","summary":"On Saturday, Teva Pharmaceuticals Industries Ltd.  and Sanofi SA  presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug  for moderate-to-severe ulcerative colitis  and Crohn’s disease , the two most common forms of inflammatory bowel disease .These results were shared at the Congress of the European Crohn’s and Colitis Organisation.Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ‘Top Pick For 2025’。In the UC cohort of the RELIEVE UCCD study, 36%  and 48%  of patients treated with duvakitug achieved the primary endpoint of clinical remission  at week 14 compared to 20% treated with placebo.Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy -experienced and AT-nave subgroups of patients.AT-experienced: 29%  and 36% , with placebo-adjusted rates of 22%  and 29% .AT-nave: 39%  and 53% , with placebo-adjusted rates of 12%  a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-teva-unveil-detailed-data-132200188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TEVA","SNY","BK4588","BK4566","IBD","BK4116","BK4585","SNYNF","BK4584","IE00BFXG1179.USD","BK4557","BK4007","BK4559","CD","BK4596"],"gpt_icon":0},{"id":"2513141222","title":"Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2513141222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513141222?lang=en_us&edition=fundamental","pubTime":"2025-02-22 15:20","pubTimestamp":1740208800,"startTime":"0","endTime":"0","summary":"Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/22/3030763/0/en/Teva-and-Sanofi-Present-New-Positive-Phase-2b-Study-Results-at-ECCO-2025-Reinforcing-Best-in-Class-Potential-of-Duvakitug-Anti-TL1A-in-Ulcerative-Colitis-and-Crohn-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SNY","BK4585","SNYNF","IBD","IE00BFXG1179.USD","CD","BK4588","BK4116"],"gpt_icon":0},{"id":"2513641582","title":"TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2513641582","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513641582?lang=en_us&edition=fundamental","pubTime":"2025-02-21 20:00","pubTimestamp":1740139200,"startTime":"0","endTime":"0","summary":"Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients. The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction. SPRING HOUSE, Pa., Feb. 21, 2025 /PRNewswire/ --Johnson & Johnson today announced data from the Phase 3 ASTRO study of TREMFYA  subcutaneous  induction therapy in adults with moderately to severely active ulcerative colitis  at the 20thCongress of the European Crohn's and Colitis Organization .Study findings through Week 12 showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration -approved intravenous  induction regimen in this population.1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tremfya-guselkumab-subcutaneous-sc-induction-120000814.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tremfya-guselkumab-subcutaneous-sc-induction-120000814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1221951129.SGD","BK4588","LU0234572021.USD","LU2468319806.SGD","LU1162221912.USD","LU1674673691.USD","LU0889566641.SGD","LU1894683348.USD","CD","LU0912757837.SGD","LU1732799900.SGD","SG9999001440.SGD","LU0792757196.USD","LU2430703178.SGD","LU1935042991.SGD","LU1267930813.SGD","LU0795875169.SGD","LU1506573853.SGD","LU2430703251.USD","LU2602419157.SGD","IE00B7SZLL34.SGD","LU1244550577.SGD","LU1032955483.USD","LU1196500208.SGD","IBD","IE0009355771.USD","LU0466842654.USD","LU2592432038.USD","LU1066053197.SGD","BK4592","IE00B19Z3581.USD","LU0122379950.USD","LU2505996509.AUD","LU0345770993.USD","IE00B3PB1722.GBP","LU0345769128.USD","BK4504","LU1894683264.USD","LU1674673428.USD","LU0320765646.SGD","LU1430594728.SGD","BK4116","LU0058720904.USD","LU2129689514.USD","IE00B42XCP33.USD","LU0345770308.USD","LU1074936037.SGD","LU1066051225.USD","JNJ","LU1221951046.USD"],"gpt_icon":0},{"id":"2512454955","title":"Howmet Aerospace Lands On Best Stocks List: Check Out Stock Spotlight, IBD 50, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2512454955","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512454955?lang=en_us&edition=fundamental","pubTime":"2025-02-20 08:06","pubTimestamp":1740009976,"startTime":"0","endTime":"0","summary":"IBD’s top-performing stock lists have just been updated. See which stocks like Howmet Aerospace got added – and which got cut.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate1-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/03/ibdstocksupdate1-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/howmet-aerospace-lands-on-best-stocks-list-check-out-stock-spotlight-ibd-50-others/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["HWM","LU0061474960.USD","BK4588","BK4187","HIMS","LU0957791311.USD","BK4196","IBD","BK4585","LU1153585028.USD","LU1815333072.USD","LU0096362180.USD","LU0011850046.USD"],"gpt_icon":0},{"id":"2512386964","title":"S&P 500 Insurance Broker, IBD Stock Of The Day, Gains On Buy Point After 43% Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2512386964","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512386964?lang=en_us&edition=fundamental","pubTime":"2025-02-20 01:16","pubTimestamp":1739985405,"startTime":"0","endTime":"0","summary":"Brown & Brown stock has started 2025 by gaining more than 8%.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2025/02/sotd-for-02-19-2025-desktop-150x150.png","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/02/sotd-for-02-19-2025-desktop-150x150.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/research/ibd-stock-of-the-day/sp-500-brownbrown-stock-insurance-surged-last-year-gaining-on-buy-point/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SSO","UPRO",".SPX","SDS","BK4534","ESmain","BK4550","BK4581","BRO","SH","IBD","IE00BKPKM429.USD","OEF","IVV","BK4559","BK4585","SPY","VOO","BK4588","OEX","LU2108987350.USD","BK4173","SPXU","BK4504","BK4597"],"gpt_icon":0},{"id":"2512877102","title":"Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512877102","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512877102?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease  and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation , held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates .Forward-Looking StatementsCertain statements in this press release, other than purely historical information, may constitute \"forward-looking statements\" within the meaning of the federal securities laws, including for purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","BK4139","LENZ","SYRE"],"gpt_icon":0},{"id":"2512839104","title":"VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512839104","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512839104?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028700/0/en/VYNE-Therapeutics-Initiates-Phase-1b-Trial-of-VYN202-a-Novel-BD2-Selective-Oral-BET-Inhibitor-in-Plaque-Psoriasis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","IBD","BK4007"],"gpt_icon":0},{"id":"2512612814","title":"Stock Market Shows Positive Reversal, But S&P 500, Nasdaq Trail These Other Indexes; IBD 50 Index Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2512612814","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512612814?lang=en_us&edition=fundamental","pubTime":"2025-02-19 09:45","pubTimestamp":1739929525,"startTime":"0","endTime":"0","summary":"Both Reddit and Shift4 are members of the IBD 50.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2020/05/Stock-Bull-fighting-06-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/05/Stock-Bull-fighting-06-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/market-trend/the-big-picture/stock-market-shows-positive-reversal-but-s-ibd-50-index-falls/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4581","IE00B64PRP62.GBP","BK4588","IE00BKPKM429.USD","NVIW.SI","LU2210150020.SGD","SSO","MNQmain","SPY","TSYW.SI","OEX","IBD","VOO","OEF","UPRO","ESmain","SDS","QID","BK4559","BK4112","PSQ","IE00BGHQF748.EUR","QQQ","TQQQ","IE00B3QW5Z07.USD","BK4504",".IXIC","LU2210149790.SGD","BK4550","IVV","SQQQ","SPXU","QLD","NQmain","USAW.SI","BK4585","USJW.SI","NDAQ",".SPX","SH","LU2095319765.USD","BK4534"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":131,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-06-26","symbol":"IBD","amount":0.0953,"announcedDate":"2025-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-07-01"},{"date":"2025-05-23","symbol":"IBD","amount":0.0809,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1748007000000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-28","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1747972800000,"payDate":"2025-05-28"},{"date":"2025-04-25","symbol":"IBD","amount":0.0799,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745587800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745553600000,"payDate":"2025-04-30"},{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}